In what care setting do doctors see patients with rare diseases? How do they keep up with treatment advances? Can pharmaceutical companies support rare disease treaters and the patient community? Those were just some of the questions addressed by exclusive research carried out by Cambridge, Massachusetts-based healthcare market research company